Nephron Pharmaceuticals Corp. addresses nationwide shortage of Sodium Bicarbonate Injection
June 1, 2017
Nephron Pharmaceuticals Corporation (Nephron) will address the recently announced critical drug shortage of 8.4% Sodium Bicarbonate Injection, USP on Friday, June 2, 2017.
This medication is available for pre-order as of Wednesday, May 31, and will ship from the Nephron 503B Outsourcing Facility on June 2, 2017.
Nephron has prepared this sterile injectable drug, to help alleviate this critical nationwide drug shortage. The Company is only the third supplier in the country to produce 8.4% Sodium Bicarbonate Injection, USP.
The 503B Outsourcing Facility at Nephron is FDA inspected and operates certified clean rooms using current Good Manufacturing Practices (cGMP). All products are manufactured on fully validated equipment and are verified with advanced in-house analytical and microbiological testing.
The new division has tripled in size since launch in January 2017 and distributes nationwide.
Nephron produces 1+ billion sterile doses annually from its award winning West Columbia, South Carolina location.
Hospitals and surgery centers can contact the Nephron 503B Outsourcing Facility toll free at 1-844-224-2225 or email [email protected].
About Nephron
Nephron Pharmaceuticals Corporation is a woman owned, private manufacturer of generic respiratory medications, ophthalmics and injectable drugs. Nephron products are proudly made in the USA! The Company is the recipient of an ISPE / FOYA 2017 innovation award. All products are offered individually wrapped and bar-coded, and are available to retail pharmacies, hospitals, home care companies, long term care facilities, mail order pharmacies, and other various customers. The company has been approved by the Food and Drug Administration as a sterile manufacturer of generic respiratory medications along with a new outsourcing facility providing equal sterility and quality. For more information, please visit www.nephronpharm.com.
